Rift Valley Fever MP-12 Vaccine Phase 2 Clinical Trial: Safety, Immunogenicity, and Genetic Characterization of Virus Isolates

An outbreak or deliberate release of Rift Valley fever (RVF) virus could have serious public health and socioeconomic consequences. A safe RVF vaccine capable of eliciting long-lasting immunity after a single injection is urgently needed. The live attenuated RVF MP-12 vaccine candidate has shown pro...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Vaccine
Autori principali: Pittman, Phillip R., Norris, Sarah L., Brown, Elizabeth S., Ranadive, Manmohan V., Schibly, Barbara A., Bettinger, George E., Lokugamage, Nandadeva, Korman, Lawrence, Morrill, John C., Peters, Clarence J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4731098/
https://ncbi.nlm.nih.gov/pubmed/26706271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2015.11.078
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi